Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results